Brief: FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
18/10/2024 13:37
Oct 18 (Reuters) - Fibrobiologics Inc FBLG.O :
* FIBROBIOLOGICS AND CHARLES RIVER ANNOUNCE COLLABORATION TO
MANUFACTURE FIBROBLAST CELL-BASED THERAPIES FOR CHRONIC DISEASES
* FIBROBIOLOGICS INC: CYWC628, FOR UTILIZATION IN A DIABETIC
FOOT
ULCER (DFU) CLINICAL TRIAL SLATED TO BEGIN IN 2025.
Source text for Eikon: ID:nGNX3PFXHY
Further company coverage: FBLG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts